Literature DB >> 10851078

Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice.

A R Shoemaker1, K M Haigis, S M Baker, S Dudley, R M Liskay, W F Dove.   

Abstract

Defects in APC and DNA mismatch repair genes are associated with a strong predisposition to colon cancer in humans, and numerous mouse strains with mutations in these genes have been generated. In this report we describe the phenotype of Min/+ Mlh1-/- mice. We find that these doubly mutant mice develop more than three times the number of intestinal adenomas compared to Min/+ Mlh1+/+ or +/- mice but that these tumors do not show advanced progression in terms of tumor size or histological appearance. Full length Apc protein was not detected in the tumor cells from Min/+ Mlh1-/- mice. Molecular analyses indicated that in many tumors from Min/+ Mlh1-/- mice, Apc was inactivated by intragenic mutation. Mlh1 deficiency in Min/+ mice also led to an increase in cystic intestinal crypt multiplicity as well as enhancing desmoid tumorigenesis and epidermoid cyst development. Thus, Mlh1 deficiency influences the somatic events involved in the development of most of the phenotypes associated with the Min mutation. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851078     DOI: 10.1038/sj.onc.1203574

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  Colorectal cancer models for novel drug discovery.

Authors:  Daniel Golovko; Dmitriy Kedrin; Ömer H Yilmaz; Jatin Roper
Journal:  Expert Opin Drug Discov       Date:  2015-08-21       Impact factor: 6.098

2.  Genetic Manipulation of Homologous Recombination In Vivo Attenuates Intestinal Tumorigenesis.

Authors:  Michael A McIlhatton; Kevin Murnan; Daniel Carson; Gregory P Boivin; Carlo M Croce; Joanna Groden
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-23

3.  Double frameshift mutations in APC and MSH2 in the same individual.

Authors:  Claudio Soravia; Celia D DeLozier; Zurana Dobbie; Claudine Rey Berthod; Eviano Arrigoni; Marie-Anne Bründler; Jean-Louis Blouin; William D Foulkes; Pierre Hutter
Journal:  Int J Colorectal Dis       Date:  2005-09       Impact factor: 2.571

Review 4.  Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.

Authors:  Kenneth W Hance; Hasan E Zeytin; John W Greiner
Journal:  Mutat Res       Date:  2005-08-25       Impact factor: 2.433

5.  Multiple jejunal cancers resulting from combination of germline APC and MLH1 mutations.

Authors:  Noralane M Lindor; Tom C Smyrk; Sheila Buehler; Shanaka R Gunawardena; Brittany C Thomas; Paul Limburg; Salman Kirmani; Stephen N Thibodeau
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

Review 6.  APC and its modifiers in colon cancer.

Authors:  Lawrence N Kwong; William F Dove
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

7.  Rapidly progressive adenomatous polyposis in a patient with germline mutations in both the APC and MLH1 genes: the worst of two worlds.

Authors:  R Scheenstra; F E M Rijcken; J J Koornstra; H Hollema; R Fodde; F H Menko; R H Sijmons; C M A Bijleveld; J H Kleibeuker
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Widespread hyperplasia induced by transgenic TGFalpha in ApcMin mice is associated with only regional effects on tumorigenesis.

Authors:  Andrea Bilger; Ruth Sullivan; Amy J Prunuske; Linda Clipson; Norman R Drinkwater; William F Dove
Journal:  Carcinogenesis       Date:  2008-02-28       Impact factor: 4.944

9.  Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function.

Authors:  Kevin M Haigis; Peter D Hoff; Alanna White; Alex R Shoemaker; Richard B Halberg; William F Dove
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

10.  Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors.

Authors:  Alain D Silk; Lauren M Zasadil; Andrew J Holland; Benjamin Vitre; Don W Cleveland; Beth A Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.